Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam.

Literature DB >> 33820773

In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam.

Abigail M Rubio¹, Ellen G Kline¹, Chelsea E Jones¹, Liang Chen^2,3, Barry N Kreiswirth², M Hong Nguyen^1,4,5, Cornelius J Clancy^1,4,6, Vaughn S Cooper^7,8, Ghady Haidar¹, Daria Van Tyne¹, Ryan K Shields^9,4,5.

Abstract

We compared the in vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa isolates collected before and after treatment-emergent resistance to ceftolozane-tazobactam. Median baseline and postexposure ceftolozane-tazobactam MICs were 2 and 64 μg/ml, respectively. Whole-genome sequencing identified treatment-emergent mutations in ampC among 79% (11/14) of paired isolates. AmpC mutations were associated with cross-resistance to ceftazidime-avibactam but increased susceptibility to piperacillin-tazobactam and imipenem. A total of 81% (12/16) of ceftolozane-tazobactam-resistant isolates with ampC mutations were susceptible to imipenem-relebactam.

Entities: Chemical

Keywords: Pseudomonas aeruginosa; antibiotic resistance; ceftolozane-tazobactam; imipenem-relebactam

Mesh：

Substances：

Year: 2021 PMID： 33820773 PMCID： PMC8315963 DOI： 10.1128/AAC.00084-21

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

30 in total

1. Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates.

Authors: Michael Feldgarden; Vyacheslav Brover; Daniel H Haft; Arjun B Prasad; Douglas J Slotta; Igor Tolstoy; Gregory H Tyson; Shaohua Zhao; Chih-Hao Hsu; Patrick F McDermott; Daniel A Tadesse; Cesar Morales; Mustafa Simmons; Glenn Tillman; Jamie Wasilenko; Jason P Folster; William Klimke
Journal: Antimicrob Agents Chemother Date: 2019-10-22 Impact factor: 5.191

2. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.

Authors: Gabriel Cabot; Sebastian Bruchmann; Xavier Mulet; Laura Zamorano; Bartolomé Moyà; Carlos Juan; Susanne Haussler; Antonio Oliver
Journal: Antimicrob Agents Chemother Date: 2014-03-17 Impact factor: 5.191

3. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.

Authors: Pablo A Fraile-Ribot; Gabriel Cabot; Xavier Mulet; Leonor Periañez; M Luisa Martín-Pena; Carlos Juan; José L Pérez; Antonio Oliver
Journal: J Antimicrob Chemother Date: 2018-03-01 Impact factor: 5.790

4. The Sequence Alignment/Map format and SAMtools.

Authors: Heng Li; Bob Handsaker; Alec Wysoker; Tim Fennell; Jue Ruan; Nils Homer; Gabor Marth; Goncalo Abecasis; Richard Durbin
Journal: Bioinformatics Date: 2009-06-08 Impact factor: 6.937

5. Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.

Authors: M Berrazeg; K Jeannot; Véronique Yvette Ntsogo Enguéné; I Broutin; S Loeffert; D Fournier; P Plésiat
Journal: Antimicrob Agents Chemother Date: 2015-07-27 Impact factor: 5.191

6. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.

Authors: Ghady Haidar; Nathan J Philips; Ryan K Shields; Daniel Snyder; Shaoji Cheng; Brian A Potoski; Yohei Doi; Binghua Hao; Ellen G Press; Vaughn S Cooper; Cornelius J Clancy; M Hong Nguyen
Journal: Clin Infect Dis Date: 2017-07-01 Impact factor: 9.079

7. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.

Authors: Melissa D Barnes; Magdalena A Taracila; Joseph D Rutter; Christopher R Bethel; Ioannis Galdadas; Andrea M Hujer; Emilia Caselli; Fabio Prati; John P Dekker; Krisztina M Papp-Wallace; Shozeb Haider; Robert A Bonomo
Journal: mBio Date: 2018-12-11 Impact factor: 7.867

8. In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.

Authors: Yoshinori Yamano
Journal: Clin Infect Dis Date: 2019-11-13 Impact factor: 9.079

9. Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors: Heng Li; Richard Durbin
Journal: Bioinformatics Date: 2009-05-18 Impact factor: 6.937

10. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.

Authors: Matteo Bassetti; Roger Echols; Yuko Matsunaga; Mari Ariyasu; Yohei Doi; Ricard Ferrer; Thomas P Lodise; Thierry Naas; Yoshihito Niki; David L Paterson; Simon Portsmouth; Julian Torre-Cisneros; Kiichiro Toyoizumi; Richard G Wunderink; Tsutae D Nagata
Journal: Lancet Infect Dis Date: 2020-10-12 Impact factor: 71.421

10 in total

Review 1. New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.

Authors: J Nicholas O'Donnell; Thomas P Lodise
Journal: Antimicrob Agents Chemother Date: 2022-06-21 Impact factor: 5.938

Review 2. New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review.

Authors: Angela Raffaella Losito; Francesca Raffaelli; Paola Del Giacomo; Mario Tumbarello
Journal: Antibiotics (Basel) Date: 2022-04-26

3. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.

Authors: Alba Ruedas-López; Isaac Alonso-García; Cristina Lasarte-Monterrubio; Paula Guijarro-Sánchez; Eva Gato; Juan Carlos Vázquez-Ucha; Juan Andrés Vallejo; Pablo Arturo Fraile-Ribot; Begoña Fernández-Pérez; David Velasco; José María Gutiérrez-Urbón; Marina Oviaño; Alejandro Beceiro; Concepción González-Bello; Antonio Oliver; Jorge Arca-Suárez; Germán Bou
Journal: Antimicrob Agents Chemother Date: 2021-12-20 Impact factor: 5.938

4. In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020.

Authors: James A Karlowsky; Sibylle H Lob; C Andrew DeRyke; David W Hilbert; Michael T Wong; Katherine Young; Fakhar Siddiqui; Mary R Motyl; Daniel F Sahm
Journal: Antimicrob Agents Chemother Date: 2022-05-02 Impact factor: 5.938